Beam Therapeutics (NASDAQ: BEAM) CEO trades shares, awarded options

Rhea-AI Filing Summary

Beam Therapeutics CEO John M. Evans reported several stock and option transactions. On January 29–30, 2026, he exercised stock options with a $0.67 exercise price, acquiring 19,336, 5,664 and 25,000 shares of common stock. On the same dates, he sold blocks of 16,333, 8,667, 22,094 and 2,906 shares at weighted average prices ranging from about $27.87 to $29.92, all under a Rule 10b5‑1 trading plan adopted on May 16, 2025. After these trades, he directly beneficially owned 986,667 common shares and indirectly held 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust. On January 31, 2026, he was also granted a new stock option for 180,000 shares at an exercise price of $27.62, vesting in equal monthly installments over 48 months, subject to continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans John M.

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		M(1)		19,336	A	$0.67	1,006,003	D
Common Stock	01/29/2026		M(1)		5,664	A	$0.67	1,011,667	D
Common Stock	01/29/2026		S(1)		16,333	D	$29.1925(2)	995,334	D
Common Stock	01/29/2026		S(1)		8,667	D	$29.7428(3)	986,667	D
Common Stock	01/30/2026		M(1)		25,000	A	$0.67	1,011,667	D
Common Stock	01/30/2026		S(1)		22,094	D	$28.2734(4)	989,573	D
Common Stock	01/30/2026		S(1)		2,906	D	$29	986,667	D
Common Stock								103,000	I	By John M. Evans, III 2018 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.67	01/29/2026		M(1)			19,336	(5)	05/08/2028	Common Stock	19,336	$0	0	D
Stock Option (Right to Buy)	$0.67	01/29/2026		M(1)			5,664	(6)	05/08/2028	Common Stock	5,664	$0	93,672	D
Stock Option (Right to Buy)	$0.67	01/30/2026		M(1)			25,000	(6)	05/08/2028	Common Stock	25,000	$0	68,672	D
Stock Option (Right to Buy)	$27.62	01/31/2026		A		180,000		(7)	01/31/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022, and December 31, 2022.

6. On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

7. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BEAM CEO John M. Evans report in this Form 4?

Beam CEO John M. Evans reported multiple option exercises and share sales. He exercised options at $0.67 per share, acquired common stock, then sold portions in several trades, all executed under a pre‑established Rule 10b5‑1 trading plan adopted on May 16, 2025.

How many Beam Therapeutics (BEAM) shares does John M. Evans own after these trades?

After the reported transactions, John M. Evans directly beneficially owned 986,667 shares of Beam common stock. He also indirectly held 103,000 additional shares through the John M. Evans, III 2018 Irrevocable Trust, as disclosed in the Form 4 ownership table.

At what prices did the BEAM CEO sell Beam Therapeutics shares in January 2026?

The CEO’s reported sales used weighted average prices between roughly $27.87 and $29.92 per share. Individual trades included weighted averages of $29.1925, $29.7428, $28.2734 and $29.00, with full price breakdowns available on request from Beam or the SEC staff.

What new stock option award did BEAM grant its CEO according to this filing?

Beam granted John M. Evans a new stock option for 180,000 shares at a $27.62 exercise price. The option vests in equal monthly installments over 48 months from January 31, 2026, contingent on his continued service with the company.

Were the BEAM CEO’s January 2026 stock sales pre‑planned under Rule 10b5‑1?

Yes. The filing states the January 2026 transactions were effected under a Rule 10b5‑1 trading plan. That plan was adopted by John M. Evans on May 16, 2025, allowing trades to proceed automatically according to preset instructions.

What Beam Therapeutics options did the CEO exercise around $0.67 per share?

Evans exercised multiple stock options with a $0.67 exercise price, converting 19,336, 5,664 and 25,000 option shares into common stock. These options relate to earlier grants tied to IPO price and development milestones, as described in the Form 4 footnotes.